RxDoctor Payments Data

Barbara Greco

Nephrology · Springfield, MANPI 1366428682

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (59.7%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 71.9% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $1,960, 5.8 times the $337 reported in 2019.

$3,283in general payments, 2019–2025

Across 52 payments — averaging $63.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Vifor Pharma, Inc.$126
  • OPKO Pharmaceuticals, LLC$117
  • Novartis$113
  • Akebia Therapeutics Inc$92
  • GSK$85
  • plus $391 from 10 others
$125,742in research payments, 2019–2025

Across 143 payments — averaging $879.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Akebia Therapeutics Inc$50K
  • CSL Behring$39K
  • AstraZeneca$28K
  • Janssen Research & Development, LLC$8K

What the payments were for

  • Consulting fees$1,96060%
  • Speaking & faculty fees$1505%
  • Food & beverage$1,07333%
  • Education$993%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,283 in reported general payments places this provider in the 75th percentile of 339 nephrology providers in Massachusetts.

See all nephrology providers in Massachusetts

Most prescribed under Part D

DrugClaimsCost to plans & patients
Envarsus XrTacrolimus39$48,002
FarxigaDapagliflozin Propanediol63$44,217
JardianceEmpagliflozin41$26,644
RayaldeeCalcifediol19$26,310
Cinacalcet Hcl52$6,855
JanuviaSitagliptin Phosphate11$5,732
Sevelamer Carbonate30$2,889
Nifedipine ErNifedipine97$2,606
Mycophenolic AcidMycophenolate Sodium33$1,611
Atorvastatin Calcium123$1,430
Lisinopril157$1,415
Amlodipine Besylate195$1,288
Carvedilol123$1,237
Losartan Potassium114$1,143
Potassium Citrate ErPotassium Citrate13$1,080

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$2,359$44,21763 claims
OPKO Pharmaceuticals, LLCRayaldee$117$26,31019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 339 nephrology providers in Massachusetts.

Other nephrology in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →